January 25, 2015 9:33 PM ET


Company Overview of ILEX Oncology Inc.

Company Overview

As of December 20, 2004, ILEX Oncology Inc. was acquired by Genzyme Corp. ILEX Oncology, Inc. engages in the development and commercialization of therapeutic treatments, primarily in oncology. Its lead product is marketed as CAMPATH in the United States and as MABCAMPATH in Europe and other countries for the treatment of patients with B-cell chronic lymphocytic leukemia, a type of blood cancer characterized by progressive accumulation of B-lymphocytes. The company’s pipeline comprises product candidates at various stages of preclinical and clinical development, including Clofarabine, ILX-651, APOMINE, and NM-3. Clofarabine is a purine nucleoside antimetabolite for pediatric and adult leukemi...

4545 Horizon Hill Boulevard

San Antonio, TX 78229

United States

Founded in 1992

216 Employees





Key Executives for ILEX Oncology Inc.

ILEX Oncology Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Adheron Therapeutics, Inc. United States
Perrigo New York, Inc. United States
Stereokem Inc. United States
DesigneRx Pharmaceuticals, Inc. United States
Deciphera Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILEX Oncology Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.